Christopher Mutz sold $425k of ANIP
HEAD OF RARE DISEASE at ANI PHARMACEUTICALS INC. 5,723 shares at an average of $74.19, traded Mar 6, 2026, filed Mar 10, 2026.
Score components
- +15RoleOfficer
- +16Trade size$425k at market
- 0Share of holdings soldSold 5.5% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.5%, 3m +6.9%, 6m -7.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001846487-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -2,121 | $74.22 | $157k | 101,387 | Mar 10, 2026 |
| Mar 7, 2026 | FTax withholding Common Stock10b5-1 | -3,314 | $74.04 | $245k | 98,073 | Mar 10, 2026 |
| Mar 9, 2026 | SOpen-market sale Common Stock10b5-1 | -3,602 | $74.18 | $267k | 94,471 | Mar 10, 2026 |
Related signals
Other insiders at ANI PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 21, 2026 | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $37k 500 shares | -1% | |
| 29Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $208k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $383k 5,400 shares | -2% | |
| 18Weak | ANI PHARMACEUTICALS INC | Jeanne Thoma director | $72k 1,000 shares | -4% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $35k 500 shares | -1% | |
| 29Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $207k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $401k 5,400 shares | -2% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $38k 500 shares | -1% | |
| 43Moderate | ANI PHARMACEUTICALS INC | Ori Gutwerg SVP, GENERICS | $243k 3,162 shares | -4% | |
| 23Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $232k 2,850 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.